Revolutionary Technology From Prescient Medical to Be Featured at Canaccord Adams Cardiovascular Conference

Revolutionary Technology From Prescient Medical to Be Featured at Canaccord
Adams Cardiovascular Conference
vProtect(TM) Luminal Shield and vPredict(TM) Optical Catheter System Poised to
Reshape Interventional Cardiology

DOYLESTOWN, Pa., Nov. 9 /PRNewswire/ -- Two products from Prescient Medical --
the vProtect(TM) Luminal Shield and the vPredict(TM) Optical Catheter System
-- will be featured at the 3rd Annual Canaccord Adams Cardiovascular
Conference. The conference will take place on Tuesday, November 10th in San
Francisco, California, and will bring together a select group of med-tech and
biotech companies focused on the most important markets in cardiovascular
medicine. Prescient Medical is one of only fifteen development-stage private
companies invited to present to potential investors at the conference.

The vProtect(TM) Luminal Shield is a novel self-expanding coronary stent
system that received CE Mark certification in August, 2009 for use in
improving coronary artery luminal diameter in patients with symptomatic
ischemic heart disease. The Shield also was recently honored with Frost &
Sullivan's 2009 North American Product Innovation of the Year Award. Designed
specifically to minimize arterial injury and its consequences, the Shield is
ideal for treating softer plaques, including plaques in patients who have
recently suffered a heart attack and so-called "vulnerable" plaques.

Vulnerable plaques are prone to rupture, causing a release of cholesterol and
cellular debris into the blood stream that often results in a clot that
obstructs blood flow to the heart, thus causing a heart attack.

The vPredict(TM) Optical Catheter System is being developed for the detection
and characterization of vulnerable plaque. The vPredict(TM) Optical Catheter
System platform is based on Raman spectroscopy, a highly sensitive technology
that is used in scores of critical non-clinical applications. The vPredict(TM)
Optical Catheter System detects the clinically important compounds, including
cholesterols, in the vessel wall and plaque.

"We are pleased to have our products featured at the Canaccord Adams
Cardiovascular Conference," said Prescient CEO Patricia Scheller. "We believe
our products have the potential to revolutionize the practice of
interventional cardiology by enabling physicians to better treat and
ultimately to prevent heart attacks."

For more information on Prescient Medical or its products, please contact
Ilana Odess, General Manager of Prescient Medical, at (917) 941-9990 or via
e-mail: iodess@pmivp.com.

About Prescient Medical, Inc.
Prescient Medical, Inc. is a privately held medical device company dedicated
to reducing deaths from heart attacks, the leading cause of death in much of
the world. The company is the recipient of the 2009 Frost and Sullivan Award
for Product Innovation of the Year Award for vProtect(TM) Luminal Shield. For
more information about Prescient Medical and its products, please visit
www.prescientmedical.com.

SOURCE Prescient Medical, Inc.

Ilana Odess, General Manager, Prescient Medical, +1-917-941-9990,
iodess@pmivp.com